ZA200610052B - Treatment with irinotecan (CPT-11) and an EGFR-inhibitor - Google Patents

Treatment with irinotecan (CPT-11) and an EGFR-inhibitor

Info

Publication number: ZA200610052B
Authority: ZA; South Africa
Prior art keywords: cpt; irinotecan; egfr; inhibitor; treatment
Prior art date: 2004-06-03

Application number

ZA200610052A

Other languages

English (en)

Inventor

Chen Jianping

Kolinsky Kenneth

Higgins Brian

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-03

Filing date

2006-11-30

Publication date

2008-08-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34968128&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200610052(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-11-30 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2008-08-27 Publication of ZA200610052B publication Critical patent/ZA200610052B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA200610052A 2004-06-03 2006-11-30 Treatment with irinotecan (CPT-11) and an EGFR-inhibitor ZA200610052B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US57650304P	2004-06-03	2004-06-03

Publications (1)

Publication Number	Publication Date
ZA200610052B true ZA200610052B (en)	2008-08-27

Family

ID=34968128

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200610052A ZA200610052B (en)	2004-06-03	2006-11-30	Treatment with irinotecan (CPT-11) and an EGFR-inhibitor

Country Status (16)

Country	Link
US (1)	US20050272737A1 (xx)
EP (1)	EP1761264A1 (xx)
JP (1)	JP2008501651A (xx)
CN (1)	CN1960730A (xx)
AR (1)	AR049136A1 (xx)
AU (1)	AU2005249201A1 (xx)
BR (1)	BRPI0511800A (xx)
CA (1)	CA2566971A1 (xx)
IL (1)	IL179373A0 (xx)
MX (1)	MXPA06013999A (xx)
NO (1)	NO20066080L (xx)
NZ (1)	NZ551355A (xx)
RU (1)	RU2006146625A (xx)
TW (1)	TW200603804A (xx)
WO (1)	WO2005117877A1 (xx)
ZA (1)	ZA200610052B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ570381A (en) *	2006-02-09	2011-02-25	Daiichi Sankyo Co Ltd	Anti-cancer pharmaceutical composition
WO2008044068A2 (en) *	2006-10-11	2008-04-17	Fusion Antibodies Limited	Combination therapy
US20100260674A1 (en) *	2006-12-15	2010-10-14	Concert Pharmaceuticals, Inc.	Quinazoline derivatives and methods of treatment
WO2008076949A2 (en) *	2006-12-15	2008-06-26	Concert Pharmaceuticals Inc.	Quinazoline derivatives and methods of treatment
KR20110005828A (ko) *	2008-03-28	2011-01-19	콘서트 파마슈티컬즈, 인크.	퀴나졸린 유도체 및 치료방법
GB0807018D0 (en)	2008-04-17	2008-05-21	Fusion Antibodies Ltd	Antibodies and treatment
WO2010043050A1 (en) *	2008-10-16	2010-04-22	Celator Pharmaceuticals Corporation	Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
US8709419B2 (en)	2010-08-17	2014-04-29	Hoffmann-La Roche, Inc.	Combination therapy
US9295669B2 (en)	2010-12-14	2016-03-29	Hoffman La-Roche Inc.	Combination therapy for proliferative disorders
AU2013202947B2 (en) *	2012-06-13	2016-06-02	Ipsen Biopharm Ltd.	Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9980953B2 (en) *	2016-09-26	2018-05-29	Chong Kun Dang Pharmaceutical Corp.	Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor
US11395821B2 (en)	2017-01-30	2022-07-26	G1 Therapeutics, Inc.	Treatment of EGFR-driven cancer with fewer side effects

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030108545A1 (en) *	1994-02-10	2003-06-12	Patricia Rockwell	Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6811779B2 (en) *	1994-02-10	2004-11-02	Imclone Systems Incorporated	Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
WO2000069459A1 (en) *	1999-05-14	2000-11-23	Imclone Systems Incorporated	Treatment of refractory human tumors with epidermal growth factor receptor antagonists
AU2002239486A1 (en) *	2000-12-08	2002-06-18	Uab Research Foundation	Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
CN100335132C (zh) *	2001-01-09	2007-09-05	默克专利有限公司	含有受体酪氨酸激酶抑制剂和血管生成抑制剂的药物组合物及试剂盒
PA8578001A1 (es) *	2002-08-07	2004-05-07	Warner Lambert Co	Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
WO2005060951A2 (en) *	2003-12-19	2005-07-07	Bionaut Pharmaceuticals, Inc.	Anti-neoplastic agents, combination therapies and related methods
WO2005117887A1 (en) *	2004-06-03	2005-12-15	F. Hoffmann-La Roche Ag	Treatment with gemcitabine and an egfr-inhibitor
NZ551354A (en) *	2004-06-03	2009-10-30	Hoffmann La Roche	Treatment with oxaliplatin and erlotinib
AU2005249206A1 (en) *	2004-06-03	2005-12-15	F. Hoffmann-La Roche Ag	Treatment with cisplatin and an EGFR-inhibitor
US20060084675A1 (en) *	2004-10-18	2006-04-20	Thomas Efferth	Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor
US20060084691A1 (en) *	2004-10-18	2006-04-20	Bilal Piperdi	Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
US20060084666A1 (en) *	2004-10-18	2006-04-20	Harari Paul M	Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
US20060134064A1 (en) *	2004-12-20	2006-06-22	David Goldstein	Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor
EP1996193A2 (en) *	2006-03-13	2008-12-03	OSI Pharmaceuticals, Inc.	Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
US20070286864A1 (en) *	2006-06-09	2007-12-13	Buck Elizabeth A	Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors

2005
- 2005-05-25 JP JP2007513800A patent/JP2008501651A/ja active Pending
- 2005-05-25 RU RU2006146625/15A patent/RU2006146625A/ru unknown
- 2005-05-25 EP EP05744557A patent/EP1761264A1/en not_active Withdrawn
- 2005-05-25 BR BRPI0511800-0A patent/BRPI0511800A/pt not_active IP Right Cessation
- 2005-05-25 CA CA002566971A patent/CA2566971A1/en not_active Abandoned
- 2005-05-25 AU AU2005249201A patent/AU2005249201A1/en not_active Abandoned
- 2005-05-25 WO PCT/EP2005/005639 patent/WO2005117877A1/en active Application Filing
- 2005-05-25 NZ NZ551355A patent/NZ551355A/en unknown
- 2005-05-25 MX MXPA06013999A patent/MXPA06013999A/es active IP Right Grant
- 2005-05-25 CN CNA2005800179203A patent/CN1960730A/zh active Pending
- 2005-05-31 TW TW094117915A patent/TW200603804A/zh unknown
- 2005-06-01 AR ARP050102244A patent/AR049136A1/es not_active Application Discontinuation
- 2005-06-03 US US11/144,855 patent/US20050272737A1/en not_active Abandoned
2006
- 2006-11-16 IL IL179373A patent/IL179373A0/en unknown
- 2006-11-30 ZA ZA200610052A patent/ZA200610052B/xx unknown
- 2006-12-29 NO NO20066080A patent/NO20066080L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
RU2006146625A (ru)	2008-07-20
CN1960730A (zh)	2007-05-09
BRPI0511800A (pt)	2008-01-15
US20050272737A1 (en)	2005-12-08
AU2005249201A1 (en)	2005-12-15
WO2005117877A1 (en)	2005-12-15
NO20066080L (no)	2007-01-03
CA2566971A1 (en)	2005-12-15
EP1761264A1 (en)	2007-03-14
IL179373A0 (en)	2007-03-08
JP2008501651A (ja)	2008-01-24
AR049136A1 (es)	2006-06-28
MXPA06013999A (es)	2007-02-08
TW200603804A (en)	2006-02-01
NZ551355A (en)	2009-09-25

Publication	Publication Date	Title
ZA200610052B (en)	2008-08-27	Treatment with irinotecan (CPT-11) and an EGFR-inhibitor
IL179525A0 (en)	2007-07-04	Treatment with gemcitabine and an egfr-inhibitor
IL213843A0 (en)	2011-07-31	4-aminotetracyclines and methods of use thereof
IL179533A0 (en)	2007-05-15	Treatment with cisplatin and an egfr-inhibitor
IL183652A0 (en)	2007-09-20	Respiratory devices and methods of use
EP1755733A4 (en)	2010-04-21	METHOD AND DEVICES FOR THERMAL TREATMENT
EP1727498A4 (en)	2009-12-16	DEVICES AND METHODS FOR ENDOVASCULAR TREATMENT
HK1110811A1 (en)	2008-07-25	Medicine injection devices and methods
EP1761176A4 (en)	2010-05-12	SUTURE METHODS AND DEVICES
GB2435590B (en)	2009-08-05	An interleaver and associated methods
EP1827391A4 (en)	2010-03-17	DOSAGE FORMS AND METHODS OF USE THEREOF
IL177845A0 (en)	2006-12-31	Combination therapy with glatiramer acetate and riluzole
GB0406088D0 (en)	2004-04-21	Infusion apparatus and methods
EP1817073A4 (en)	2013-01-02	IMPROVED DEVICES AND METHODS OF ENERGY DELIVERY
IL178492A0 (en)	2007-02-11	Cancer treatment using viruses and camptothecins
GB0406085D0 (en)	2004-04-21	Infusion apparatus and methods
EP1737565A4 (en)	2010-11-03	COS CLAUS CONFIGURATIONS AND METHODS
EP1733749A4 (en)	2013-09-04	SYRINGE WITH COUPLING, SYRINGE FITTING AND SYRINGE
EP1797186A4 (en)	2008-11-12	EXPRESSION SYSTEM, COMPONENTS OF THIS EXPRESSION SYSTEM, AND METHODS OF USE
ZA200610050B (en)	2008-08-27	Treatment with oxaliplatin and an EGFR-inhibitor
HK1113686A1 (en)	2008-10-10	Biotinylated hexadecasaccharides, preparation and use thereof
ZA200704136B (en)	2008-11-26	Particle-size reduction apparatus, and use thereof
GB2433897B (en)	2010-02-17	Gaming systems and methods
GB0407382D0 (en)	2004-05-05	Therapeutic methods and means
GB0424552D0 (en)	2004-12-08	Methods and means